mouse mammary tumor cells Search Results


mouse mammary tumor cell line mmc  (ATCC)
93
ATCC mouse mammary tumor cell line mmc
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Mouse Mammary Tumor Cell Line Mmc, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary tumor cell line mmc/product/ATCC
Average 93 stars, based on 1 article reviews
mouse mammary tumor cell line mmc - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
mouse mammary tumor cell line eo771  (Beijing Zhongyuan)
90
Beijing Zhongyuan mouse mammary tumor cell line eo771
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Mouse Mammary Tumor Cell Line Eo771, supplied by Beijing Zhongyuan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary tumor cell line eo771/product/Beijing Zhongyuan
Average 90 stars, based on 1 article reviews
mouse mammary tumor cell line eo771 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mouse mammary tumor fm3a cells (wild-type, subclone f28-7)  (JCRB Cell Bank)
90
JCRB Cell Bank mouse mammary tumor fm3a cells (wild-type, subclone f28-7)
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Mouse Mammary Tumor Fm3a Cells (Wild Type, Subclone F28 7), supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary tumor fm3a cells (wild-type, subclone f28-7)/product/JCRB Cell Bank
Average 90 stars, based on 1 article reviews
mouse mammary tumor fm3a cells (wild-type, subclone f28-7) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mouse scc cell line kln205-muc1  (BioResource International Inc)
90
BioResource International Inc mouse scc cell line kln205-muc1
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Mouse Scc Cell Line Kln205 Muc1, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse scc cell line kln205-muc1/product/BioResource International Inc
Average 90 stars, based on 1 article reviews
mouse scc cell line kln205-muc1 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mouse mammary tumor fm3a cells  (Tanabe)
90
Tanabe mouse mammary tumor fm3a cells
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Mouse Mammary Tumor Fm3a Cells, supplied by Tanabe, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse mammary tumor fm3a cells/product/Tanabe
Average 90 stars, based on 1 article reviews
mouse mammary tumor fm3a cells - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
dna purified from a balb/c mouse mammary tumor cell line mcf-8  (New England Nuclear Corporation)
90
New England Nuclear Corporation dna purified from a balb/c mouse mammary tumor cell line mcf-8
(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. <t>MMC</t> tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. <t>(D)MMC</t> <t>syngeneic</t> tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05
Dna Purified From A Balb/C Mouse Mammary Tumor Cell Line Mcf 8, supplied by New England Nuclear Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna purified from a balb/c mouse mammary tumor cell line mcf-8/product/New England Nuclear Corporation
Average 90 stars, based on 1 article reviews
dna purified from a balb/c mouse mammary tumor cell line mcf-8 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


(A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. MMC tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. (D)MMC syngeneic tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05

Journal: Vaccine

Article Title: Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets.

doi: 10.1016/j.vaccine.2019.05.024

Figure Lengend Snippet: (A) TgMMTV-neu mice received three vaccinations with empty vector and each of the seven early tumor antigens. MMC tumor cells were implanted on day 0. (B) TgMMTV-neu mice received three vaccinations with empty vector ● and the five late stage tumor antigens that have human homologs. MMC tumor cells were implanted on day 0 ***p<0.001. (C) Vaccination Schema. (D)MMC syngeneic tumor lysate but not lysate from FVB splenocytes induces an IFN-g T cell immune response in mice vaccinated with the early and late stage tumor antigens. IFN-g secreting cells quantified as precursor frequency (y-axis) for FVB mice (n=5) vaccinated with the plasmids for the early tumor antigens (light gray) or FVB mice (n=5) vaccinated with the plasmids for the late stage antigens (dark gray) as compared to FVB mice (n=5) vaccinated with empty control vector plasmid (white). The positive control is concanavalin A (CONA). * p<0.05 (E) Vaccination with the early and late stage tumor antigens induces a CD8+ T cell immune response. Granzyme B ELISA was performed on the pooled supernatants from the ELISPOT assay. ** p=0.01 * p<0.05

Article Snippet: The syngeneic mouse mammary tumor cell line MMC and human cell lines MCF10F (non-malignant breast), HCC1500 (ER positive HER2 negative), HCC70 (ER negative HER2 negative), and SKBR3 (ER negative HER2 positive) were seeded in two 96 well plates (ATCC, Manassas VA).

Techniques: Plasmid Preparation, Control, Positive Control, Enzyme-linked Immunosorbent Assay, Enzyme-linked Immunospot

Using four pooled siRNA for each target in the syngeneic MMC mouse tumor cell line, grey bars are the early stage antigens measuring (A) survival and (B) caspase 3/7 activity as compared to cells transfected with liposomes but no siRNA (control). For the late stage tumor antigens, the grey bars show the late stage tumor antigens measuring (C) survival and (D) caspase 3/7 activity as compared to cells transfected with liposomes but no siRNA (control). White bars include liposome transfected cells (control), non-targeting control siRNA transfected cells (negative control), and untransfected cells (untx). Apoptosis inducing siRNA transfected cells is the black bar (positive control) ** p<0.01 **** p<0.0001 as compared to control.

Journal: Vaccine

Article Title: Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets.

doi: 10.1016/j.vaccine.2019.05.024

Figure Lengend Snippet: Using four pooled siRNA for each target in the syngeneic MMC mouse tumor cell line, grey bars are the early stage antigens measuring (A) survival and (B) caspase 3/7 activity as compared to cells transfected with liposomes but no siRNA (control). For the late stage tumor antigens, the grey bars show the late stage tumor antigens measuring (C) survival and (D) caspase 3/7 activity as compared to cells transfected with liposomes but no siRNA (control). White bars include liposome transfected cells (control), non-targeting control siRNA transfected cells (negative control), and untransfected cells (untx). Apoptosis inducing siRNA transfected cells is the black bar (positive control) ** p<0.01 **** p<0.0001 as compared to control.

Article Snippet: The syngeneic mouse mammary tumor cell line MMC and human cell lines MCF10F (non-malignant breast), HCC1500 (ER positive HER2 negative), HCC70 (ER negative HER2 negative), and SKBR3 (ER negative HER2 positive) were seeded in two 96 well plates (ATCC, Manassas VA).

Techniques: Activity Assay, Transfection, Liposomes, Control, Negative Control, Positive Control